Larger-scale, well-designed randomized controlled trials with standardized protocols for intervention and assessment are crucial to providing more robust evidence on the impact of SGLT2 inhibitors on hypomagnesemia across various patient populations. The gene discussed is SLC5A2; the disease is Hypomagnesemia.